Clinical Cancer Research

Article	Citations
Selected Articles from This Issue	406
Selected Articles from This Issue	245
Selected Articles from This Issue	222
And… We’re Back: The Reemergence of CD137 in Cancer Immunotherapy via Antigen Anchoring	205
Project Optimus Elicits the “Holistic” Benefits of PK/PD Modeling of Immunotherapy	204
Rewiring Antitumor Immunity: Targeting CLDN18.2 with Conditional 4-1BB Activation	196
Broadening the MIND: Tafasitamab and Lenalidomide versus Synthetic Controls	194
Abstract C025: Endometrial cancer mutation patterns by age with possible increased TP53 and decreased PTEN mutations in patients 50+ years old	182
In Search of Lost Biomarker for Immunotherapy in Small Cell Lung Cancer	166
CH Mutations in 16,812 Advanced Cancer Patients–Response	157
Organ Preservation via Immunotherapy-Based Total Neoadjuvant Therapy in Early Low Rectal Cancer (TORCH-E): A Multicenter, Open-label, Single-Arm, Phase II Study	156
Abstract B036: Non-steroidal anti-inflammatory drugs use and risk of colorectal cancer molecular subtypes: A systematic review and meta-analysis	142
A first-in-human phase 1 clinical trial evaluating clinical activity and proof-of-mechanism of tobemstomig, a PD1-LAG3 bispecific antibody, in patients with CPI-experienced melanoma	139
Molecular and Clinical Characteristics of Patients with Non–Small Cell Lung Cancer Harboring KRAS G12V Mutations	132
Acetylated HOXB13 Regulated Super Enhancer Genes Define Therapeutic Vulnerabilities of Castration-Resistant Prostate Cancer	131
Metabolomic Prediction of Breast Cancer Treatment–Induced Neurologic and Metabolic Toxicities	127
SALVO: Single-Arm Trial of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma	126
SJPedPanel: A Pan-Cancer Gene Panel for Childhood Malignancies to Enhance Cancer Monitoring and Early Detection	126
Phase I Trial of First-line Bintrafusp Alfa in Patients with Locally Advanced or Persistent/Recurrent/Metastatic Cervical Cancer	123
Durvalumab plus Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: An Open-label, Nonrandomized, Phase II Clinical Trial	122
One CD4+TCR and One CD8+TCR Targeting Autochthonous Neoantigens Are Essential and Sufficient for Tumor Eradication	119
UBE2T-Mediated HP1α Ubiquitination Enhances Nucleolar Function and Promotes the Progression of IDH1/TP53-Mutant Glioma	113
A Cohort Study of CNS Tumors in Multiple Endocrine Neoplasia Type 1	110
Association of Tumor Mutational Burden with Efficacy of Pembrolizumab±Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study	108
Optimizing ATR Inhibition and Cisplatin Synergy in Ewing Sarcoma	107

Bevacizumab, Atezolizumab, and Acetylsalicylic Acid in Recurrent, Platinum-Resistant Ovarian Cancer: The EORTC 1508-GCG Phase II Study	106
Shared HLA-Bound Neoepitopes Are New Targets for Pancreatic Cancer Immunotherapy	105
Intratumoral or Subcutaneous MK-2118, a Noncyclic Dinucleotide STING Agonist, with or without Pembrolizumab, for Advanced or Metastatic Solid Tumors or Lymphomas	102
Targeting SMAD3 Improves Response to Oxaliplatin in Esophageal Adenocarcinoma Models by Impeding DNA Repair	101
NPY Methylated ctDNA is a Promising Biomarker for Treatment Response Monitoring in Metastatic Colorectal Cancer	99
Pharmacological Landscape of FDA-Approved Anticancer Drugs Reveals Sensitivities to Ixabepilone, Romidepsin, Omacetaxine, and Carfilzomib in Aggressive Meningiomas	96
Abstract PS2-07-19: Proteomic subtyping of stage II/III TNBC from the I-SPY2 TRIAL reveals a druggable steroid hormone receptor signature (SRS) that is associated with poor outcome and enriched in non	92
Abstract PS2-08-09: Baseline HER2 expression on circulating tumor cells in metastatic breast cancer	91
Abstract PS1-13-04: Fairness-constrained logistic regression achieves superior performance and racial equity in breast cancer survival prediction	90
Abstract PS2-04-10: Adherence to endocrine prevention in patients with atypical hyperplasia and lobular carcinoma in situ: promising trends from real-world use of low dose tamoxifen	85
Abstract PS2-07-21: Tumor Necrosis Factor-related Weak Inducer of Apoptosis (TWEAK) - A Potential Biomarker for Predicting Response and Long-Term Outcomes in Early Breast Cancer Patients	85
Abstract PS3-03-18: Guidelines for Breast Cancer Index Test before and after Epic software enhancement	83
Navigating Complexity: Perspectives on Risk Assessment in the Era of New Blood-Based Tests for Early Cancer Detection	83
Abstract PS2-10-18: Epithelial-mesenchymal transition (EMT) Signature Score of a Bulk Tumor May Not Reflect the EMT of Malignant Epithelial Cells	82
Selected Articles from This Issue	81
Abstract PS5-10-21: Real-world patterns and preferences in the use of diagnostic imaging for breast cancer staging in Hispano-America: A multinational physician survey	81
Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer	81
Abstract PS3-07-12: The CONCISE Study : A Pan-UK Real-World Audit of Adjuvant Abemaciclib Use in High-Risk Early Breast Cancer	81
Pharmacogenomic Score Effectively Personalizes Treatment of Acute Myeloid Leukemia	80
Sitravatinib Targets TYRO3 to Augment the Antitumor Immune Response of PD-1 Blockade in Hepatocellular Carcinoma	78
Fine-Tuning Adjuvant Endocrine Therapy for Early-Stage Breast Cancer: An Expert Consensus on Open Issues for Future Research	77
CDK9 Inhibition by Dinaciclib Is a Therapeutic Vulnerability in Epithelioid Hemangioendothelioma	76
Novel Approach to Accelerate Lung Cancer Research: Lung-MAP and the Potential of Public-Private Partnerships	76
Learning Individual Survival Models from PanCancer Whole Transcriptome Data	76
The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma	74
A Phase 2 Trial of RANKL Antibody, Denosumab, in Two Cohorts of Patients with Recurrent/Refractory Osteosarcoma, a Report from the Children’s Oncology Group	74
Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial	74
Cell-of-Origin Subtype Predicts Response to Polatuzumab Vedotin in Large B-cell Lymphoma	74
Abstract RF2-06: Impact of Immune Checkpoint Inhibition (CPI) on Fertility in Young Women with Early Triple-Negative Breast Cancer (TNBC) receiving neoadjuvant Chemotherapy (NACT): A Prospective Subst	73
Patient-Derived Organoids and Xenografts Uncover Therapeutic Vulnerabilities in Colorectal Signet Ring Cell Carcinomas	73
Abstract PS5-12-26: Yoga in Breast Cancer Survivorship: Knowledge, Attitudes, <Perceived Benefits	73
Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict Mortality	73
Abstract PS5-05-25: Is the 21-Gene Recurrence Score Validated for Real-World use in Node Positive Breast Cancer? A Retrospective Cohort Study	72
Abstract PS5-08-15: Targeted axillary dissection vs axillary node clearance in patients with positive axillary nodes in early breast cancer: a multicentre, pragmatic, phase 3 randomised controlled tri	72
Abstract PS5-12-10: Impact of KEYNOTE-522 on BneoCT: An Institutional Quality Measure Improvement Analysis	71
Abstract PS5-07-29: Trial in progress: a phase 1 dose-escalation study evaluating BGB-21447 (BCL2 inhibitor) in combination with fulvestrant with and without BGB-43395 (CDK4 inhibitor) in patients wit	70
Abstract PS5-12-05: Cdk4/6 inhibitors in outpatient gynecological oncology: identification of implementation barriers and opportunities for improving their use in the practice	70
Abstract PS4-02-26: Gper signaling as a biomarker for endocrine therapy sensitivity in pik3ca mutant hr+ advanced breast cancer	68
PS4-05-22: Eprs1 induces ac4c modification of mRNAs encoding pluripotency factors in breast cancer cells	67
Abstract PS1-13-10: Elucidating Stemness-Associated Regulatory Pathways to Guide Personalized Treatment for Ductal Carcinoma in Situ	67
Abstract PS2-01-07: A Multicenter Retrospective Observational Study on the Safety and Timing of Radiotherapy After Oncoplastic Breast-Conserving Surgery	67
Abstract PS2-05-06: Safety and Oncologic Outcomes of Immediate Breast Reconstruction Following Neoadjuvant Chemotherapy	66
Abstract PS4-02-09: Symptom Clustering and Multi-Omics Signatures of Cancer-Related Fatigue in Breast Cancer: Findings from the China PERSEVERE Cohort	66
Abstract PS3-11-18: Neoadjuvant Response in HER2+ Early Breast Cancer: A Comparative Study Between HER2-Enriched and Luminal HER2 Subtypes	66
Abstract PS3-11-13: Fatty Acid Profile and Its Association with HER2-Positive Breast Cancer and Response to Neoadjuvant Chemotherapy	65
Abstract PS4-05-03: Pro-c3 as a circulating biomarker of tumor fibrosis in breast cancer: functional insights from studying cancer associated fibroblasts in vitro	64
Abstract PS4-06-19: Final results of a Phase I trial of an alpha-lactalbumin (aLA) vaccine for breast cancer	63
Abstract PS4-04-30: Discovery of NKT5097: a first-in-class, highly potent and selective, orally bioavailable CDK2/4 dual degrader for cancer therapy	63
Abstract PS1-11-18: Prescription Patterns and Treatment Persistence in Patients with Metastatic Breast Cancer on CDK4/6 Inhibitors	62
Abstract PS1-10-20: Free-her: discontinuation of maintenance her-2 directed therapy in long-term survivors of metastatic her-2 positive breast cancer: a trial update	61

Abstract PS1-08-07: Final results from the Randomized Phase II study of Z-Endoxifen and Tamoxifen in Endocrine Refractory, Estrogen Receptor Positive, HER2 negative Metastatic Breast Cancer (Alliance	61
Abstract PS1-06-27: The Use of Contrast Enhanced Mammography for Noncalcified Ductal Carcinoma Insitu for the Breast: Pre Surgical Staging and Planning	60
Abstract PS3-02-03: Leucine-rich repeat neuronal 1 as a prognostic indicator and functional modulator in breast cancer	60
Abstract PS3-02-06: Stromal-Fibroblastic remodelling and involution signatures in non-tumoral tissue of postpartum breast cancer patients: implications for breast cancer risk	60
Abstract PS5-06-25: Investigating association of comorbidities and race with all-cause mortality outcomes of PI3K inhibitor use in metastatic breast cancer (mBC)	60
Abstract PS4-08-29: Neoadjuvant antibody-drug conjugates for early-stage breast cancer: a systematic review and meta-analysis	59
Abstract PS2-02-21: Real-world outcomes of CDK4/6 inhibitors in patients with metastatic invasive lobular carcinoma: a retrospective single-center study	59
PS5-06-22: Atypical recurrence of invasive lobular breast carcinoma with hormone receptor loss: a Case Report	59
Abstract PS2-02-01: Improved Antiemetic Outcomes with NEPA vs (Fos)aprepitant in Patients with Breast Cancer Receiving Antibody-Drug Conjugates: A 12-Month Real-World Claims Analysis	58
Abstract PS3-05-14: Clinical significance of pathogenic variants in breast cancer patients at risk for hereditary breast cancer	58
Abstract PS4-08-06: Optimizing Postoperative Adjuvant Therapy for Early-Stage Breast Cancer by Combining Dynamic ctDNA MRD Monitoring with Clinical Risk Stratification: An Open-label, Multicenter, Pro	58
Abstract PS4-08-25: Trends and determinants of non-treatment in early-stage breast cancer (ESBC)	58
Abstract PS2-12-04: Promoter Hypermethylation-Induced Silencing of FXYD1 Drives Breast Cancer Metastasis via DDX5-Mediated Wnt/β-Catenin Pathway Activation	56
Abstract PS4-06-09: Efficacy of a novel BCL-xL degrader, DT2216, in the treatment of triple-negative breast cancer	56
Abstract PS2-07-13: Prognostic and predictive role of RBsig and CCNE1/RB1 gene-expression signatures for patients with early breast cancer treated with endocrine therapy with or without palbociclib in	56
Abstract PS2-11-13: Resistance to tucatinib associated with hyperactive EGFR could be overcome by co-targeting HER2 and EGFR in HER2-positive breast cancer models	55
PS5-06-28: Carcinoma en Cuirasse and Radiation-Induced Morphea	55
Abstract PS5-01-26: Long-term outcomes of first-line (1L), guideline-recommended treatment versus alternative regimens in HER2+ metastatic breast cancer (mBC): a retrospective observational study of U	54
Abstract PS2-05-30: Long-term Outcome Prediction with Residual Cancer Burden (RCB) post Neo-adjuvant Chemotherapy in Breast Cancer patients - LOPNeoRCB: An ambispective study	54
Abstract PS5-02-14: "longterm" - long-term response (>18 months) in metastatic her2-positive breast cancer: a retrospective analysis of patients diagnosed between 2010 and 2020 in the german bn	54
Abstract PD13-02: Cytomegalovirus reactivation drives brain metastasis in breast cancer via immunosuppressive microglial reprogramming	54
Abstract PD7-08: Exploratory phase II trial of camrelizumab (an anti-PD-1 antibody) combined with apatinib (a VEGFR-2 inhibitor) and chemotherapy as a neoadjuvant therapy for triple-negative breast ca	54
Abstract RF5-02: Tbcrc 056: a phase 2 study of neoadjuvant niraparib with dostarlimab for patients with BRCA- or PALB2-mutated breast cancer: results from the TNBC cohorts	53
Initial Phase I Safety Study of Gedatolisib plus Cofetuzumab Pelidotin for Patients with Metastatic Triple-Negative Breast Cancer	53
Correction: Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant	53
A Histopathologic Correlation Study Evaluating Glymphatic Function in Brain Tumors by Multiparametric MRI	53
Abstract PS1-10-18: Genomic analysis of ER+/HER2- metastatic invasive lobular carcinoma (ILC) and clinical outcomes comparison with metastatic invasive carcinoma of no special type (NST)	53
Abstract PS4-01-22: The Utility of MT1-MMP in Predicting Treatment Efficacy with HER2-positive advanced or metastatic breast cancer: JBCRG-M06/EMERALD trial TR	53
Low-Dose Intestinal Irradiation Enhances the Efficacy and Prognosis of PD-1 Blockade in Metastatic Non–Small Cell Lung Cancer	53
Necroptosis-dependent Immunogenicity of Cisplatin: Implications for Enhancing the Radiation-induced Abscopal Effect	53
Abstract PS3-09-19: Correlation Between Breast Cancer Index (BCI) and RSClin Late in Assessing 5-10 Year Recurrence Risk in Early-Stage Hormone Receptor-Positive Breast Cancer	53
New Means and Challenges in the Targeting of BTK	52
Generalised pairwise comparisons in dose-optimisation oncology trials: beyond safety to multi-outcome dose selection	52
Clinicopathologic, Genomic, and Immunophenotypic Landscape of ATM Mutations in Non–Small Cell Lung Cancer	52
SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression	52
Treatment of Prostate Cancer with CD46-targeted 225Ac Alpha Particle Radioimmunotherapy	52
Phototherapy with Cancer-Specific Nanoporphyrin Potentiates Immunotherapy in Bladder Cancer	52
A Phase II Trial of an Extended-Release siRNA Implant Targeting KRAS G12D/V in Locally Advanced Pancreatic Cancer	52
Genomic Landscape of ctDNA and Real-World Outcomes in Advanced Endometrial Cancer	51
An Attempt to Stretch the Benefit: Rechallenge with PARP Inhibitors in Ovarian Cancer	51
Re-Irradiation Plus Pembrolizumab: A Phase II Study for Patients with Recurrent Glioblastoma	51
Amplification of Extrachromosomal MYC Paralogs Shapes Immunosuppressive Tumor Microenvironment in Small Cell Lung Cancer	51
Circulating Tumor DNA Kinetics Predict Progression-Free and Overall Survival in EGFR TKI–Treated Patients with EGFR -Mutant NSCLC (SWOG S1403)	51
A Phase I Clinical Trial of Intrahepatic Artery Delivery of TG6002 in Combination with Oral 5-Fluorocytosine in Patients with Liver-Dominant Metastatic Colorectal Cancer	50
CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null Disease	50
Phase II Study of Palbociclib in Patients with Tumors with CDK4 or CDK6 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1C	50
Clinical Validation of EndoPredict in Pre-Menopausal Women with ER-Positive, HER2-Negative Primary Breast Cancer	50
Facts and Hopes for Immunotherapy in Renal Cell Carcinoma	50
Long-Term Follow-up of Levonorgestrel Intrauterine Device for Atypical Hyperplasia and Early Endometrial Cancer Reveals Relapse Characterized by Immune Exhaustion	49
Selected Articles from This Issue	49
Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors	49
Direct Comparison of Alternative Blood-Based Approaches for Early Detection and Diagnosis of HPV-Associated Head and Neck Cancers	49
Selected Articles from This Issue	49
High Mechanical Conditioning by Tumor Extracellular Matrix Stiffness Is a Predictive Biomarker for Antifibrotic Therapy in HER2-Negative Breast Cancer	49
Selected Articles from This Issue	49
Phase II Open-Label Trial of Brentuximab Vedotin with Pembrolizumab in PD-1–Pretreated Metastatic Non–Small Cell Lung Cancer and Metastatic Cutaneous Melanoma	49
RAD51 Testing in Patients with Early HER2-Negative Breast Cancer and Homologous Recombination Deficiency: A Post Hoc Analysis of the GeparOLA Trial	49
FOXM1 Variant Contributes to Gefitinib Resistance via Activating Wnt/β-Catenin Signal Pathway in Patients with Non–Small Cell Lung Cancer	48
Glioma Response to IDH Inhibition: Real-World Experience	48
Phase II Pilot Trial of Tislelizumab plus Low-Dose Nab-Paclitaxel for Extensive Very High–Risk Non–Muscle-Invasive Bladder Cancer	48
Liquid Biopsy Identifies Taxane Resistance and Clonal Selection in Castration-Resistant Prostate Cancer	48
A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies	48
Population Pharmacokinetics of Orvacabtagene Autoleucel, an Autologous BCMA-Directed Chimeric Antigen Receptor T-cell Product, in Patients with Relapsed/Refractory Multiple Myeloma	48
Adult-Onset Cancer Predisposition Syndromes in Children and Adolescents—To Test or not to Test?	47
Diversity by Design: Real-World Data to Enhance Representation in Clinical Cancer Research	47
Validation of the Prognostic Performance of Breast Cancer Index in Hormone Receptor–Positive Postmenopausal Breast Cancer Patients in the TEAM Trial	47
Phase I Clinical Trial of the Bifunctional EGFR/TGF-β Fusion Protein Ficerafusp Alfa (BCA101) Alone and in Combination with Pembrolizumab for Advanced Solid Tumors	47
Combination Nivolumab, CD137 Agonism, and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma	47
Preoperative Chemoimmunotherapy followed by salvage surgery and adjuvant tislelizumab for previously irradiated R HNSCC: A prospective, phase II trial	47
Abstract PR016: Supplement And Medication Use in Early-Onset Colorectal Cancer: An Analysis of the Ohio Colorectal Cancer Prevention Initiative	46
Research Silos in Cancer Disparities: Obstacles to Improving Clinical Outcomes for Underserved Patient Populations	46
Pembrolizumab with Chemotherapy for Patients with Recurrent or Metastatic Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma: A Prospective Phase ll Study	46
Abstract A002: Real-world clinicogenomic comparison of early- and average-onset gastric cancer	46
Time to Optimize Deescalation Strategies in Triple-Negative Breast Cancer?	46
Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study	46
Abstract B016: Survival differences after diagnosis of early-onset colorectal cancer by race/ethnicity and neighborhood-level socioeconomic status	46
Bevacizumab plus Erlotinib in Advanced Solid Cancers with Krebs Cycle Gene Mutations: A Multicenter Phase II Study (BRISK; KCSG AL22-16)	46
Abstract PS1-13-05: Reflect: radiomic evaluation for the localization of the excision cavity using tomography	45
Editor’s Note: Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in L	45
Unique Cabozantinib Dosing Considerations in People Living with HIV and Cancer	45

Abstract PS2-08-13: Spatially resolved tumor subclones in HER2-positive breast cancer	45
Abstract PS4-08-22: Hypofractionated Whole Breast Irradiation with Concomitant Boost following Breast Conservation Surgery in Early-Stage Breast Cancer	44
Abstract PS5-10-03: The Influence of Sociodemographic Factors on Barriers to Breast Cancer Screening	44
Abstract PS4-08-11: Standardized Definitions for Efficacy End Points (STEEP, STEEP2) in the CCTG MA.32 randomized breast cancer trial of metformin versus placebo: Implications of the type of recurrenc	44
Abstract PS1-02-03: Talking to Employers and Medical Staff about Work: An Intervention to Increase Access to Work Accommodations	44
Abstract PS5-02-10: Pyrotinib plus capecitabine with or withoutradiotherapyin patients with HER2-positive metastatic breast cancer and brain metastases: Amulticenter, retrospective-prospective, real-w	44
Abstract PS4-08-16: Evaluation of Clinicopathological Features and Prognoses of Male Patients with Breast Lymphoma	44
Abstract PS1-01-12: Preventing Chemotherapy-Induced Peripheral Neuropathy with Acupuncture: Preliminary Results of a Pooled Analysis of Three Parallel Randomized Trials	43
Abstract PD5-03: Deep Proteomics and AI Classifier for Early Breast Cancer Detection	43
Abstract PD8-02: Evaluating weight loss outcomes in patients with hormone receptor-positive breast cancer on endocrine therapy receiving concurrent weight loss medications	43
Abstract PS5-05-18: How Susan G. Komen’s ShareForCures® Research Hub will connect researchers with real-world data shared by breast cancer patients and survivors in the United States	43
Abstract PS1-06-18: Does chemotherapy for early breast cancer affect cognition and brain structure? The Chemobrain Study	43
Abstract RF1-02: Surgical outcomes in the ALTERNATE trial (Alliance A011106) -a randomized phase 3 neoadjuvant endocrine therapy (NET) trial in postmenopausal women with clinical stage II/III estrogen	43
Abstract PS1-07-01: Outcomes of 1-3 brain metastases treated with stereotaxy in metastatic breast cancer: a single institutional experience from eastern India	43
Abstract PS3-09-28: Clinical investigations into the metabolic pathways of early stage hormone receptor positive/HER2 negative breast cancer	42
Abstract PD11-10: Optimizing HER2 Diagnostic Pathways: AI Assistance Enriches Gene Amplified Cases in Equivocal Category and Reduces Turnaround Time	42
Abstract PD1-10: Immune Age Acceleration as a Biomarker for Immune-Related Adverse Events in Early Triple-Negative Breast Cancer Treated with Perioperative Pembrolizumab	42
Abstract PS1-05-18: Association Between Sleep Continuity and Cognition in Breast Cancer Survivors: A Cross-Sectional Study	42
Abstract PS3-08-25: Integrated Prognostic and Chemotherapy Sensitivity Assessment Using Multiple Gene Assays in ER-positive, HER2-negative Early Breast Cancer	42
Abstract PD10-08: Interim safety in the inavolisib + ribociclib or abemaciclib + fulvestrant or letrozole arms of MORPHEUS-pan breast cancer: A Phase 1b/2 study of efficacy and safety of multiple trea	42
Abstract PS2-05-29: Feasibility and outcomes of premastectomy radiation therapy in locally advanced breast cancer	42
Abstract GS3-05: Evaluation of the Sensitivity to Endocrine Therapy (SETER/PR) assay to predict benefit from extended endocrine therapy in the NRG/NSABP B-42 trial	42
Abstract PS2-13-02: Daxx is a novel predictive biomarker of response to anti-notch plus endocrine therapy to target cancer stem cells in ER-positive breast cancer	41
Abstract PS4-07-12: Real-world comparison of pembrolizumab dosing schedules (q3w vs q6w) in early TNBC: Insights from the PETRHA cohort	41
Abstract PS2-03-08: Survival outcomes after lumpectomy versus therapeutic mammoplasty in breast cancer patients: a Brazilian cohort study	41
Abstract PS2-13-01: Discrete Vulnerabilities to CDK2 Inhibition in Breast Cancer: Genetic Determinants and Therapeutic Opportunities	41
PS4-05-15: Immunohistochemical characterization of the tumor cells present in four body fluids from patients with metastatic breast cancer in the context of the UPTIDER program	41
Abstract PS1-10-03: The Aurora Kinase A Inhibitor Alisertib Alone or in Combination with Endocrine Therapy for Patients with Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negati	41
Abstract PS4-04-28: Multifunctional lipid nanoparticles remodeling tumor immune microenvironment for breast cancer chemio-immunotherapy	41
Abstract PS5-02-25: Homologous Recombination Deficiency is the major determinant of response of Triple-Negative Breast Cancer to Cisplatin+Radiotherapy	41
Abstract PS4-12-12: Racial Disparities in Pathologic Complete Response in Patients with HER2 Positive Breast Cancer Treated with Neoadjuvant Chemotherapy	40
Abstract PS2-06-23: Impact of somatic PIK3CA Mutations on clinical outcomes in HER2-Positive Breast Cancer	40
Abstract PS3-12-18: Exploratory Analysis of Immune Cell Subsets in Luminal B HER2-negative Breast Cancer and Their Association with Pathologic Response	40
Abstract PS2-01-18: Targeted Axillary Dissection after Neoadjuvant Systemic Chemotherapy in patients with Early Breast Cancer: Estimating the Real-World Impact of Omitted Axillary Lymph Node Dissectio	40
Abstract PS3-05-17: Prevalence of BRCA 1/2 mutation among breast cancer patients in Kenya	40
Abstract PS3-13-01: Cik cell therapy remodels the immune microenvironment and suppresses cutaneous metastatic breast cancer in preclinical models	40
Abstract PS3-05-09: Approaches to Breast Cancer Risk Management in Ovarian Cancer (OC) Patients Harboring Germline BRCA1/2 Mutations (gBRCA1/2mut)	40
PS5-09-22: Phase 1b study of EZH1/2 inhibitor valemetostat in combination with trastuzumab deruxtecan in subjects with HER2 low/ultra-low/null metastatic breast cancer	39
PS5-06-06: Case Series on Early Methotrexate Use in Reducing Morbidity in Granulomatous Mastitis	39
Identification of Early-Stage Breast Cancer with a Minimal Risk of Recurrence by the Breast Cancer Index	39
Co-blockade of TGFβ and PD-1 Reinvigorates Glioblastoma-Infiltrating CD8+ T Cells That Characteristically Upregulate TGFβRI Expression	39
Abstract PS4-03-15: Repurposing eliglustat as an anti-cancer agent for triple-negative breast cancer	39
Abstract PS5-12-02: Quantifying the value of progression-free survival in breast cancer treatment among a general population of US women	39
Abstract PS5-08-18: Trofuse-011: a phase 3, randomized, open-label study of sacituzumab tirumotecan with or without pembrolizumab vs treatment of physician’s choice for previously untreated locally re	39
Tumor-Agnostic Genomic and Clinical Analysis of BRAF Fusions Identifies Actionable Targets	39
Abstract PS4-09-23: Palliative Care Utilization and Associated Outcomes in Hospitalized Breast Cancer Patients: Using The National Inpatient Sample 2021	39
Abstract PS2-04-07: A large-scale, US-based study evaluating real-world medical cost savings and reduced healthcare resource utilization associated with longer first-line treatment for advanced breast	39
Abstract PS1-12-16: Chromatin Reader ZMYND8 Promotes Breast Cancer Bone Metastasis	39
Therapy-related Myeloid Neoplasms Following PARP Inhibitors—Response	39
Molecularly Defined Subsets of Ewing Sarcoma Tumors Differ in Their Responses to IGF1R and WEE1 Inhibition	39
BRAF Deletion in Adult Patients with Langerhans Cell Histiocytosis Correlates with Multisystem Disease and Poor Outcomes	39
Abstract PS3-05-01: Risk factor profile in male breast cancer: a cohort-based assessment from a breast cancer institute in northeastern México	38
Abstract PS3-01-10: Patterns of metastasis according to germline BRCA1/2 mutation status in patients with HER2-negative metastatic breast cancer	38
Abstract PS3-06-11: A Novel Agent-Based AI System to Unlock Unstructured Data in Synoptic Reports for Advanced Population Health Analysis in Breast Cancer	38
Abstract PS3-02-19: Primary Care Provider Input On Personalized Breast Cancer Screening Recommendations in WISDOM 1.0: A Nationwide Risk-Based Breast Cancer Screening Trial	38
Abstract PS3-04-27: Mutational burden and clonal expansion in lymph nodes correlate with IBC postoperative relapse	38
Germline–Somatic Interactions in BRCA-Associated Cancers: Unique Molecular Profiles and Clinical Outcomes Linking ATM to TP53	38
SNP of Aromatase Predict Long-term Survival and Aromatase Inhibitor Toxicity in Patients with Early Breast Cancer: A Biomarker Analysis of the GIM4 and GIM5 Trials	38
Proteomic Profiling of Advanced Melanoma Patients to Predict Therapeutic Response to Anti-PD-1 Therapy	38
Clonal Hematopoiesis and Inflammation Predict Hematologic Toxicity and Secondary Myeloid Malignancies after B-Cell Maturation Antigen–Directed Chimeric Antigen Receptor T-cell Therapy	37
Zinc Finger MYND-Type Containing 8 (ZMYND8) Is Epigenetically Regulated in Mutant Isocitrate Dehydrogenase 1 (IDH1) Glioma to Promote Radioresistance	37
Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non–Small Cell Lung Cancer with PIK3CA/PTEN Alterations	37
Receptor CDCP1 Is a Potential Target for Personalized Imaging and Treatment of Poor Outcome HER2+, Triple-Negative, and Metastatic ER+/HER2− Breast Cancers	37
Clinical Activity of TGF-β Inhibitor Vactosertib in Combination with Imatinib in Desmoid Tumors: A Multicenter Phase Ib/II Study	37
A Phase II Randomized Study of Paclitaxel Alone or Combined with Pelareorep with or without Avelumab in Metastatic Hormone Receptor–Positive Breast Cancer: The BRACELET-01/PrE0113 Study	37
Facts and Hopes on the Use of Artificial Intelligence for Predictive Immunotherapy Biomarkers in Cancer	37
Myt1 Kinase: An Emerging Cell-Cycle Regulator for Cancer Therapeutics	37
Neoadjuvant Chemotherapy Is Associated with Altered Immune Cell Infiltration and an Anti-Tumorigenic Microenvironment in Resected Pancreatic Cancer	37
Fcγ Receptor Polymorphism in Patients with Relapsed/Refractory High-Risk Neuroblastoma Correlates with Outcomes in the SIOPEN Dinutuximab Beta Long-Term Infusion Trial	37
Cadonilimab Combined with Chemotherapy with or without Bevacizumab as First-Line Treatment in Recurrent or Metastatic Cervical Cancer (COMPASSION-13): A Phase 2 Study	36
Methodical Manipulation of the TME in Ovarian Cancer	36
A Phase II Trial of Olaparib plus Pembrolizumab in Patients with Recurrent Copy Number–High/p53-Abnormal Endometrial Cancer	36
STX-721, a Covalent EGFR/HER2 Exon 20 Inhibitor, Utilizes Exon 20–Mutant Dynamic Protein States and Achieves Unique Mutant Selectivity Across Human Cancer Models	36
Validation of Diagnostic Utility of Washout CYFRA 21-1 in Lymph Node Metastasis of Thyroid Cancer	36
Gene Expression Profiling Identifies Two Chordoma Subtypes Associated with Distinct Molecular Mechanisms and Clinical Outcomes	36
Selinexor Combined with Ibrutinib Demonstrates Tolerability and Safety in Advanced B-Cell Malignancies: A Phase I Study	36
Metformin Does Not Significantly Alter Longitudinal Dynamics of Clonal Hematopoiesis	36
Allogeneic CAR T Cells Targeting DLL3 Are Efficacious and Safe in Preclinical Models of Small Cell Lung Cancer	35
A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms	35
Molecular and Pathologic Characterization of YAP1-Expressing Small Cell Lung Cancer Cell Lines Leads to Reclassification as SMARCA4-Deficient Malignancies	35
Mechanism of Initial Favorable Response to Decitabine in TP53 -Mutated MDS/AML and Potential Mechanisms of Subsequent Relapse	35
Platinum-Based Chemotherapy Attenuates the Effector Response of CD8 T Cells to Concomitant PD-1 Blockade	35
Antibody–Drug Conjugates in Non–Small Cell Lung Cancer: Where Are the Target and the Biomarker?	34
Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study	34
Pancreatic Cancer's PD1-Roadblock: When T-Cell Reinvigoration Is Not Enough	34
Combination Therapy with Copanlisib and Niraparib in Patients with Recurrent Endometrial and Ovarian Cancer (COPANIRA): Efficacy, Toxicity, and Translational Insights	34
Comprehensive Single-Cell RNA Atlas of Human Laryngeal Normal, Preneoplastic, and Tumorigenic States	34
Phase I/II Study of the PARP Inhibitor Olaparib and Irinotecan in Children and Young Adults with Recurrent/Refractory Malignancies: Arm D of the AcSé-ESMART Trial	34
Transcriptional Phenocopies of Deleterious KEAP1 Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy	34
Reconstitution of the Multiple Myeloma Microenvironment Following Lymphodepletion with BCMA CAR-T Therapy	34
Immunity, Age, and Luminal Breast Cancer: Understanding the Holy Trinity	34
Correction: Tamoxifen Response at Single Cell Resolution in Estrogen Receptor-Positive Primary Human Breast Tumors	34
Long-term Survival and Molecular Biomarker Evaluation of a Phase II Cetuximab and Nivolumab Clinical Trial in Recurrent/Metastatic Head and Neck Cancer	34
FDA Approval Summary: Idecabtagene Vicleucel for the Treatment of Triple-Class–Exposed, Relapsed or Refractory Multiple Myeloma	34
Niraparib plus Dostarlimab in Pleural Mesothelioma or Non–Small Cell Lung Cancer Harboring HRR Mutations: Interim Results of the UNITO-001 Phase II Prosp	34